Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2b, Double-blind, Placebo-controlled Efficacy Challenge Study With the Shigella Tetravalent Bioconjugate Vaccine Shigella4V2

NCT06615375 is registered in ClinicalTrials.gov with LimmaTech Biologics AG as lead sponsor.

NCT NCT06615375
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06615375 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2b, Double-blind, Placebo-controlled Efficacy Challenge Study With the Shigella Tetravalent Bioconjugate Vaccine Shigella4V2
Lead sponsor
LimmaTech Biologics AG
Phase
Phase 2
Overall status
Completed
Start date
November 12, 2024
Completion date
September 18, 2026
Enrollment
97 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

shigellosis